Addressing artifacts of colorimetric anticancer assays for plant-based drug development
Cancer has become the silent killer in less-developed countries and the most significant
cause of morbidity worldwide. The accessible and frequently used treatments include …
cause of morbidity worldwide. The accessible and frequently used treatments include …
The role of the methoxy group in approved drugs
D Chiodi, Y Ishihara - European Journal of Medicinal Chemistry, 2024 - Elsevier
The methoxy substituent is prevalent in natural products and, consequently, is present in
many natural product-derived drugs. It has also been installed in modern drug molecules …
many natural product-derived drugs. It has also been installed in modern drug molecules …
[HTML][HTML] Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised …
K Holmsten, NV Jensen, LS Mouritsen… - European Journal of …, 2020 - Elsevier
Background The present study (VINGEM) is the first randomised trial comparing
vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with …
vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with …
Histone deacetylase inhibitor, trichostatin A, synergistically enhances paclitaxel-induced cytotoxicity in urothelial carcinoma cells by suppressing the ERK pathway
FS Hsu, JT Wu, JY Lin, SP Yang, KL Kuo… - International Journal of …, 2019 - mdpi.com
Trichostatin A (TSA), an antifungal antibiotic derived from Streptomyces, inhibits mammalian
histone deacetylases, and especially, selectively inhibits class I and II histone deacetylase …
histone deacetylases, and especially, selectively inhibits class I and II histone deacetylase …
Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
F Riedel, M Münker, F Roghmann, J Breyer… - Cancers, 2022 - mdpi.com
Simple Summary With the introduction of immune checkpoint inhibitors (ICI) in recent years,
the treatment landscape of metastatic urothelial cancer has undergone a substantial …
the treatment landscape of metastatic urothelial cancer has undergone a substantial …
Anticancer alkaloids: molecular mechanisms and clinical manifestations
Throughout history, naturally derived molecules have had countless applications in
medicine, pharmacy, and biology. This rich reservoir of natural compounds demonstrated …
medicine, pharmacy, and biology. This rich reservoir of natural compounds demonstrated …
Genomic landscape of vinflunine response in metastatic urothelial cancer
A Bernardini, M Dueñas, MC Martín-Soberon, C Rubio… - Cancers, 2022 - mdpi.com
Simple Summary Few metastatic urothelial cancer patients achieve durable clinical benefit
with vinflunine. Predictive biomarkers to help to identify better treatment strategies are …
with vinflunine. Predictive biomarkers to help to identify better treatment strategies are …
Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series
A Bamias, A Hegele, J Medioni, D Castellano… - Critical Reviews in …, 2019 - Elsevier
Background Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic
urothelial cancer after failure of platinum-containing therapy. We performed a systematic …
urothelial cancer after failure of platinum-containing therapy. We performed a systematic …
Izolace alkaloidů Vinca minor a jejich biologická aktivita II.
V Míšek - 2023 - dspace.cuni.cz
Míšek, V.: Izolace alkaloidů Vinca minor a jejich biologická aktivita II. Diplomová práce,
Farmaceutická fakulta v Hradci Králové, Univerzita Karlova, Katedra farmakognozie a …
Farmaceutická fakulta v Hradci Králové, Univerzita Karlova, Katedra farmakognozie a …
Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study
R Abdel-Malek, KS Shohdy, N Abbas… - Current Drug …, 2019 - ingentaconnect.com
Background: Several single chemotherapeutic agents have been evaluated as the second-
line treatment of advanced urothelial carcinoma. Despite encouraging efficacy outcomes …
line treatment of advanced urothelial carcinoma. Despite encouraging efficacy outcomes …